Poly Medicure Zukünftiges Wachstum
Future Kriterienprüfungen 5/6
Poly Medicure wird ein jährliches Gewinn- und Umsatzwachstum von 21.7% bzw. 18.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 21.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 20.3% betragen.
Wichtige Informationen
22.6%
Wachstumsrate der Gewinne
22.6%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 20.7% |
| Wachstumsrate der Einnahmen | 18.8% |
| Zukünftige Eigenkapitalrendite | 20.3% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 26 May 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations
May 25
Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital
May 12Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up
Mar 23Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today
Feb 15Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly
Jan 16Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?
Nov 14Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward
Oct 24Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being
Sep 22Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00
Sep 08Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly
Aug 12Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching
Jul 13Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return
Jun 16Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital
Mar 02We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt
Feb 14Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal
Oct 16We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt
Sep 28Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50
Sep 08Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly
Jun 25A Look At The Intrinsic Value Of Poly Medicure Limited (NSE:POLYMED)
Jun 07Poly Medicure (NSE:POLYMED) Will Want To Turn Around Its Return Trends
May 23With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting
Feb 23There Are Reasons To Feel Uneasy About Poly Medicure's (NSE:POLYMED) Returns On Capital
Feb 04Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly
Jan 12With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting
Oct 14Poly Medicure (NSE:POLYMED) Could Easily Take On More Debt
Jul 07Poly Medicure (NSE:POLYMED) Will Will Want To Turn Around Its Return Trends
Jun 18Poly Medicure's (NSE:POLYMED) Solid Profits Have Weak Fundamentals
May 31Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹1,195
May 26Shareholders of Poly Medicure (NSE:POLYMED) Must Be Delighted With Their 448% Total Return
Mar 01I Ran A Stock Scan For Earnings Growth And Poly Medicure (NSE:POLYMED) Passed With Ease
Feb 16How Much Is Poly Medicure Limited (NSE:POLYMED) CEO Getting Paid?
Feb 01Did Poly Medicure Limited (NSE:POLYMED) Insiders Sell Shares?
Jan 17Poly Medicure Limited's (NSE:POLYMED) Stock Is Going Strong: Is the Market Following Fundamentals?
Dec 09
Announcing: Poly Medicure (NSE:POLYMED) Stock Increased An Energizing 205% In The Last Five Years
Nov 24Is Poly Medicure (NSE:POLYMED) Using Too Much Debt?
Nov 09Many Would Be Jealous Of Poly Medicure's (NSE:POLYMED) Returns On Capital
Oct 26Have Insiders Been Selling Poly Medicure Limited (NSE:POLYMED) Shares?
Oct 06Should You Be Adding Poly Medicure (NSE:POLYMED) To Your Watchlist Today?
Sep 17Should Poly Medicure Limited (NSE:POLYMED) Be Part Of Your Dividend Portfolio?
Sep 02Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2027 | 24,837 | 5,284 | 3,554 | 5,054 | 1 |
| 3/31/2026 | 20,725 | 4,274 | 2,239 | 3,983 | 5 |
| 3/31/2025 | 16,950 | 3,330 | 986 | 3,219 | 4 |
| 3/31/2024 | 13,758 | 2,583 | -109 | 2,661 | N/A |
| 12/31/2023 | 13,046 | 2,487 | N/A | N/A | N/A |
| 9/30/2023 | 12,498 | 2,337 | -197 | 2,390 | N/A |
| 6/30/2023 | 11,872 | 2,150 | N/A | N/A | N/A |
| 3/31/2023 | 11,152 | 1,793 | -484 | 1,908 | N/A |
| 12/31/2022 | 10,659 | 1,566 | N/A | N/A | N/A |
| 9/30/2022 | 10,113 | 1,411 | -533 | 1,568 | N/A |
| 6/30/2022 | 9,600 | 1,359 | N/A | N/A | N/A |
| 3/31/2022 | 9,231 | 1,465 | -321 | 1,235 | N/A |
| 12/31/2021 | 8,785 | 1,492 | N/A | N/A | N/A |
| 9/30/2021 | 8,518 | 1,500 | -228 | 777 | N/A |
| 6/30/2021 | 8,280 | 1,468 | N/A | N/A | N/A |
| 3/31/2021 | 7,865 | 1,359 | 236 | 1,187 | N/A |
| 12/31/2020 | 7,448 | 1,197 | N/A | N/A | N/A |
| 9/30/2020 | 7,218 | 1,094 | 347 | 1,543 | N/A |
| 6/30/2020 | 6,960 | 1,028 | N/A | N/A | N/A |
| 3/31/2020 | 6,872 | 959 | 223 | 1,283 | N/A |
| 12/31/2019 | 6,881 | 947 | N/A | N/A | N/A |
| 9/30/2019 | 6,625 | 858 | 603 | 1,197 | N/A |
| 6/30/2019 | 6,388 | 719 | N/A | N/A | N/A |
| 3/31/2019 | 6,108 | 654 | 285 | 1,065 | N/A |
| 3/31/2018 | 5,204 | 706 | -75 | 750 | N/A |
| 3/31/2017 | 4,550 | 551 | N/A | 561 | N/A |
| 3/31/2016 | 4,123 | 483 | N/A | 632 | N/A |
| 3/31/2015 | 3,903 | 623 | N/A | 633 | N/A |
| 3/31/2014 | 3,222 | 451 | N/A | 661 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: POLYMEDDas prognostizierte Gewinnwachstum (21.7% pro Jahr) liegt über der Sparquote (6.7%).
Ertrag vs. Markt: POLYMEDDie Erträge des Unternehmens (21.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (16% pro Jahr).
Hohe Wachstumserträge: POLYMEDEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: POLYMEDDie Einnahmen des Unternehmens (18.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (9.4% pro Jahr).
Hohe Wachstumseinnahmen: POLYMEDDie Einnahmen des Unternehmens (18.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: POLYMEDDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (20.3%)